PEPTIDELABSign in

GLP-1 / incretin

Tirzepatide

Multiple large human RCTs

Approved (Mounjaro / Zepbound).

What's actually proven

  • ✓~21% average weight loss at 15 mg over 72 weeks (SURMOUNT-1).
  • ✓Beat semaglutide head-to-head for weight loss (SURMOUNT-5) and HbA1c (SURPASS-2).

The bullshit / overstated

  • ✗Same regain problem after stopping as other GLP-1s.
  • ✗Grey-market 'tirz' purity is unverified.

Side effects

  • •GI side effects (nausea, diarrhoea)
  • •Injection-site reactions
  • •Gallbladder issues

Don't use if

  • !Medullary thyroid cancer / MEN2 history
  • !Pancreatitis history
  • !Pregnancy

Typical protocol (from clinical trials)

Once weekly

Build planCalculate dose

Sources

SURMOUNT-1, NEJM 2022